Loratadine
- Generic Name
- Loratadine
- Brand Names
- Alavert, Alavert D, Allerclear, Claritin, Claritin-D, Diphen, Loradamed, Wal-itin, Wal-itin D
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23ClN2O2
- CAS Number
- 79794-75-5
- Unique Ingredient Identifier
- 7AJO3BO7QN
- Background
Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.
- Indication
Loratadine is a 2nd generation antihistamine and is used to manage symptoms of allergic rhinitis, wheal formation, urticaria, and other allergic dermatologic conditions.
- Associated Conditions
- Allergic Dermatologic Disorders, Allergic Reaction, Allergic Rhinitis (AR), Allergy to Tree Pollen, Chronic Urticaria, Common Cold, Epiphora, Eye pruritus, Fever, Nasal Congestion, Nasal Itching, Pain, Perennial Allergic Rhinitis (PAR), Pruritus, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Sensation of burning in the eyes, Watery itchy eyes
A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT06955741
- Locations
- 🇺🇸
Local Institution - 10000, Anaheim, California, United States
🇺🇸Anaheim Clinical Trials LLC (ACT), Anaheim, California, United States
🇺🇸Local Institution - 9999, Anaheim, California, United States
Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine
- Conditions
- Common Cold
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 177
- Registration Number
- NCT06531707
- Locations
- 🇲🇽
Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico
Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU)
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Hangzhou Grand Biologic Pharmaceutical, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT06250400
Over-the-Counter Antihistamines & Heat Stress
- Conditions
- Sudomotor Sympathetic DysfunctionHeat IllnessAllergic RhinitisHeat Injury
- Interventions
- Other: Placebo (Sugar Pill)
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Lakehead University
- Target Recruit Count
- 16
- Registration Number
- NCT06217367
- Locations
- 🇨🇦
Lakehead University C.J Sanders Fieldhouse, Thunder Bay, Ontario, Canada
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
- Conditions
- Fabry's Disease
- Interventions
- Drug: AGALSIDASE BETA (GZ419828)
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 8
- Registration Number
- NCT06019728
- Locations
- 🇺🇸
UCLA Medical Center Site Number : 1003, Santa Monica, California, United States
🇺🇸Emory University School of Medicine Site Number : 1005, Atlanta, Georgia, United States
🇺🇸Infusion Associates Site Number : 1001, Grand Rapids, Michigan, United States
Gabapentin Versus Loratadine in Uremic Pruritus
- Conditions
- PruritusUremiaChronic Kidney Diseases
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- King Edward Medical University
- Target Recruit Count
- 64
- Registration Number
- NCT05750875
- Locations
- 🇵🇰
King Edward Medical University/Mayo Hospital, Lahore, Punjab, Pakistan
Loratadine for the Prevention of G-CSF-related Bone Pain
- Conditions
- Stem Cell Transplant Complications
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 78
- Registration Number
- NCT05421416
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
- Conditions
- Allergic Conjunctivitis
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Andover Research Eye Institute
- Target Recruit Count
- 58
- Registration Number
- NCT05265910
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
Evaluation of The Effect of Loratadine Versus Diosmin/Hesperidin Combination on Vinca Alkaloids Induced Neuropathy
- Conditions
- Vinca Alkaloid Adverse Reaction
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 90
- Registration Number
- NCT05243706
Effect of Loratadine in Lymphangioleiomyomatosis
- Conditions
- Lymphangioleiomyomatosis
- Interventions
- Drug: Placebo 10mg/day added to rapamycin for 12 months
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Institut d'Investigació Biomèdica de Bellvitge
- Target Recruit Count
- 62
- Registration Number
- NCT05190627
- Locations
- 🇪🇸
Hospital Puerta de Hierro, Madrid, Spain
🇪🇸Hospital La Princes, Madrid, Spain
🇪🇸Hospital Marqués de Valdecillas, Santander, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.